Context Therapeutics (NASDAQ:CNTX) Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of Context Therapeutics (NASDAQ:CNTX) from a hold rating to a sell rating in a research report sent to investors on Sunday morning.

Other analysts have also issued research reports about the company. Guggenheim reaffirmed a “buy” rating and issued a $5.00 target price on shares of Context Therapeutics in a report on Tuesday, March 24th. D. Boral Capital reissued a “buy” rating and issued a $9.00 price objective on shares of Context Therapeutics in a research report on Tuesday, March 24th. Lifesci Capital upgraded shares of Context Therapeutics to a “strong-buy” rating in a research note on Monday, February 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Context Therapeutics in a research report on Wednesday, January 21st. Finally, JonesTrading began coverage on shares of Context Therapeutics in a research note on Monday, December 22nd. They set a “buy” rating and a $7.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Context Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $6.60.

Context Therapeutics Price Performance

CNTX stock opened at $2.62 on Friday. The stock has a market capitalization of $240.73 million, a price-to-earnings ratio of -6.89 and a beta of 1.96. The company has a 50-day moving average of $2.52 and a two-hundred day moving average of $1.66. Context Therapeutics has a 52-week low of $0.49 and a 52-week high of $3.62.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings data on Monday, March 23rd. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). Equities analysts expect that Context Therapeutics will post -0.51 EPS for the current fiscal year.

Institutional Trading of Context Therapeutics

A number of hedge funds have recently modified their holdings of the company. State Street Corp grew its holdings in shares of Context Therapeutics by 8.5% during the 4th quarter. State Street Corp now owns 165,607 shares of the company’s stock worth $243,000 after purchasing an additional 13,000 shares in the last quarter. Blue Owl Capital Holdings LP raised its stake in shares of Context Therapeutics by 0.3% in the fourth quarter. Blue Owl Capital Holdings LP now owns 7,432,906 shares of the company’s stock valued at $10,926,000 after purchasing an additional 25,000 shares in the last quarter. Virtu Financial LLC bought a new position in Context Therapeutics in the fourth quarter worth $43,000. Clear Harbor Asset Management LLC lifted its position in Context Therapeutics by 60.5% in the third quarter. Clear Harbor Asset Management LLC now owns 92,804 shares of the company’s stock worth $90,000 after purchasing an additional 35,000 shares during the period. Finally, Quadrature Capital Ltd acquired a new stake in Context Therapeutics during the fourth quarter worth $68,000. Institutional investors own 14.03% of the company’s stock.

About Context Therapeutics

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.